Dr. Daniel Walzman, M.D.
Interventional Radiology (Vascular & Interventional Radiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 159
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Vascular & Interventional Radiology Physician primary
NJ license 25MA07874800 -
Neurological Surgery Physician
NJ license 25MA07874800
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hackensack University Medical Center Hackensack, NJ
- Englewood Hospital and Medical Center Englewood, NJ
- Holy Name Medical Center Teaneck, NJ
Medical groups
- New Jersey Brain and Spine PC (41 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 159
- Services billed
- 409
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 205 | 131 |
| Established patient office or other outpatient visit, 20-29 minutes | 46 | 42 |
| Insertion of tube into internal neck artery for diagnosis or treatment with review by radiologist | 42 | 36 |
| New patient office or other outpatient visit, 45-59 minutes | 31 | 31 |
| Insertion of tube into brain artery for diagnosis or treatment with review by radiologist | 30 | 29 |
| Imaging of blood vessel | 27 | 17 |
| Review by radiologist of image for insertion of material to block blood flow | 22 | 19 |
| Occlusion of central nervous system or spinal cord artery | 21 | 19 |
| Removal of blood clot and injection to dissolve blood clot from head artery using fluoroscopic guidance | 13 | 13 |
| Established patient office or other outpatient visit, 10-19 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brilinta (ticagrelor) Other prescribers in Hackensack, NJ | 111 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Hackensack, NJ | 69 |
| Eliquis (apixaban) Other prescribers in Hackensack, NJ | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $48.73 in total to this clinician.
| Penumbra, Inc. | $35.00 |
|---|---|
| Microvention, Inc. | $13.73 |
| Food and Beverage | $48.73 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,750 in research payments for these studies, mostly to the institutions running them.
- MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
Microvention, Inc. · Active, not recruiting · NCT05409989
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.